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 Supplementary Table 1. Unit cost for individual surgical procedures. 
 
 Items Unit costs 
(£) 
Source 
Monitoring Monitor  95 Indicative manufacturer’s price 
Surgery Lower gastrointestinal (elective) 1,777 NHS Reference cost 
Upper gastrointestinal (elective) 2,854 NHS Reference cost 
Small bowel +/- pancreas (elective) 2,450 NHS Reference cost 
Urological or gynaecological (elective) 6,485 NHS Reference cost 
Aortic or Abdominal surgery (non-elective) 6,423 NHS Reference cost 
Blood & fluid Colloid (500 ml) 4.70 British National Formulary 
Crystalloid (1000 ml) 1.83 Personal communication 
Red cell (280 ml) 122.09 NHS Blood & Transplant 
Frozen fresh plasma (250 ml) 29.98 NHS Blood & Transplant 
Drug & other 
related  
Dopexamine (50 mg) 25.20 British National Formulary 
Syringe 0.36 Personal communication 
Giving set 1.53 Personal communication 
Saline 2.30 Personal communication 
Hospital costs Critical care level 2 868 NHS Reference cost 
Critical care level 3 1,416 NHS Reference cost 
General surgical ward 260 NHS Reference cost 
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Supplementary Table 2. Hospital costs (£) up to six months in the trial intervention groups.  
Data presented as mean (SD).  
 
 Peri-operative cardiac 
output-guided, 
haemodynamic therapy 
algorithm 
(n=368) 
Usual care 
 
 
 
(n=365) 
Surgery costs 2,453 (999) 2,440 (1019) 
Intervention   
    Cardiac monitor costs 94 (10) 8 (27) 
    Drug (Dopexamine) costs 28 (6) - 
    Intravenous crystalloid costs 5 (3) 7 (3) 
    Intravenous colloid costs 21 (11) 9 (8) 
    Blood products costs 82 (379) 39 (205) 
Critical care costs 3,202 (4,111) 3,519 (5,598) 
General surgical ward costs 2,687 (3,751) 2,952 (3,267) 
Total costs 8,574 (6,304) 8,974 (7,217) 
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Supplementary Table 3. Subgroup analyses reporting incremental costs (£), quality 
adjusted life years (QALYs) and incremental net benefit at six months. 
Data presented as mean (95% confidence intervals). *Incremental effects are adjusted for baseline variables 
including all variables used in minimisation algorithm.  
 
 
 Incremental 
costs* 
Incremental 
QALY* 
 
Incremental net 
benefit*  
Overall 
-404 
(-1,313 to 505) 
0.01 
(0.00 to 0.02) 
580 
(-378 to 1,583) 
Urgency of surgery    
 Elective (n=708) 
-416 
(-1,327 to 496) 
0.01 
(0.00 to 0.02) 
579 
(-383 to 1,541) 
 Non-elective (n=25) 
-3,042 
(-11,026 to 4,942) 
-0.02 
(-0.08 to 0.05) 
2,733 
(-5,091 to 10,557) 
Type of surgery    
 Upper gastro (n=222) 
-273 
(-2,361 to 1,815) 
0.01 
(-0.01 to 0.03) 
454 
(-1,699 to 2,607) 
 Lower gastro (n=334) 
-796 
(-1,903 to 311) 
0.01 
(-0.01 to 0.02) 
906 
(-272 to 2,083) 
 Small bowel +/- pancreas (n=168) 
256 
(-1,430 to 1,943) 
0.01 
(-0.01 to 0.04) 
3 
(-1,808 to 1,814) 
Timing of recruitment    
 Early (n=160) 
879 
(-1,257 to 3,015) 
-0.02 
(-0.04 to 0.01) 
-1,207 
(-3,442 to 1,028) 
 Late (n=565) 
-821 
(-1,840 to 197) 
0.02 
(0.00 to 0.03) 
1,133 
(61 to 2,205) 
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Supplementary Table 4. Goodness of fit of statistical models based on alternative 
distributions of survival functions. 
 
 
Distribution Akaike Information Criteria 
Gompertz 1476.3 
Lognormal 1509.3     
Log-logistic 1482.7  
Weibull 1474.6 
Exponential 1474.8 
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Supplementary Table 5. Ratios (with 95% confidence intervals) of the mortality rates from 
applying alternative parametric extrapolations for OPTIMISE patients compared with the 
age-gender matched general population. 
 
 
Year Gompertz Log-normal Log-Logistic Weibull Exponential 
Year 1 
0.64 
(0.55-0.72) 
0.70 
(0.62-0.78) 
0.67 
(0.59-0.75) 
0.65 
(0.57-0.73) 
0.58 
(0.51-0.65) 
Year 2 
0.98 
(0.88-1.08) 
0.96 
(0.86-1.05) 
0.97 
(0.88-1.07) 
0.97 
(0.87-1.07) 
0.98 
(0.87-1.08) 
Year 3 
1.17 
(1.04-1.30) 
1.08 
(0.98-1.19) 
1.14 
(1.03-1.25) 
1.17 
(1.05-1.29) 
1.24 
(1.12-1.35) 
Year 4 
1.26 
(1.08-1.44) 
1.15 
(1.04-1.26) 
1.23 
(1.11-1.35) 
1.29 
(1.15-1.42) 
1.41 
(1.29-1.53) 
Year 5 
1.30 
(1.08-1.52) 
1.18 
(1.06-1.29) 
1.28 
(1.15-1.40) 
1.36 
(1.22-1.50) 
1.5 
(1.39-1.63) 
 
 
 
 
 
7 
 
Supplementary Table 6. Sensitivity analyses reporting lifetime incremental costs (£), 
quality adjusted life years (QALYs), and incremental net benefit.  
Data presented as mean (95% confidence intervals). *Incremental effects are adjusted for baseline variables 
including all variables used in minimisation algorithm.  
 
 
 Incremental costs* 
 
Incremental QALY* 
 
Incremental net 
benefit* 
Base case 
-404 
(-1,313 to 504) 
0.19 
(-0.17 to 0.54) 
4,168 
(-3,063 to 11,398) 
Total costs including costs 
incurred in recovery unit 
-412 
(-1,319 to 495) 
0.19 
(-0.17 to 0.54) 
4,175 
(-3,056 to  11,405) 
Additional staff time for the 
intervention 
-216 
(-1,125 to 693) 
0.19 
(-0.17 to 0.54) 
3,979 
(-3,252 to  11,209) 
Alternative QoL assumption 
-405 
(-1,314 to 504) 
0.19 
(-0.16 to 0.55) 
4,289 
(-3,025 to  11,603) 
QALY calculation for decedents 
up to time of death  
-405 
(-1,314 to 504) 
0.18 
(-0.17 to 0.54) 
4,097 
(-3,184 to 11,379) 
QoL weights from OPTIMISE 
-405 
(-1,314 to 504) 
0.18 
(-0.14 to 0.50) 
4,053 
(-2,470 to  10,576) 
Weibull survival 
-405 
(-1,314 to 504) 
0.19 
(-0.17 to 0.54) 
4,163 
(-3,061 to  11,386) 
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Supplementary Figure 1. Cost-effectiveness acceptability curve (all patient six months 
analysis) describing the probability that cardiac output-guided haemodynamic therapy is 
cost effective for a range of decision makers’ willingness to pay thresholds per quality-
adjusted life year (QALY) gained when compared to usual peri-operative care. 
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Supplementary Figure 2. Kaplan-Meier survival curves of OPTIMISE patients stratified by 
treatment allocation group. 
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Supplementary Figure 3:  Population expected value of perfect information (EVPI) 
illustrating the expected value of perfect information that would resolve uncertainty 
regarding the treatment decision for a range of decision makers’ willingness to pay 
thresholds per quality-adjusted life year (QALY) gained.  
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